BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 26498688)

  • 1. PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA.
    Kim ST; Lira M; Deng S; Lee S; Park YS; Lim HY; Kang WK; Mao M; Heo JS; Kwon W; Jang KT; Lee J; Park JO
    Oncotarget; 2015 Nov; 6(37):40026-35. PubMed ID: 26498688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR
    Moynahan ME; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Ringeisen F; Hortobagyi GN; Baselga J; Chandarlapaty S
    Br J Cancer; 2017 Mar; 116(6):726-730. PubMed ID: 28183140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of cancer DNA in plasma of patients with early-stage breast cancer.
    Beaver JA; Jelovac D; Balukrishna S; Cochran R; Croessmann S; Zabransky DJ; Wong HY; Toro PV; Cidado J; Blair BG; Chu D; Burns T; Higgins MJ; Stearns V; Jacobs L; Habibi M; Lange J; Hurley PJ; Lauring J; VanDenBerg D; Kessler J; Jeter S; Samuels ML; Maar D; Cope L; Cimino-Mathews A; Argani P; Wolff AC; Park BH
    Clin Cancer Res; 2014 May; 20(10):2643-2650. PubMed ID: 24504125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.
    Oshiro C; Kagara N; Naoi Y; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2015 Apr; 150(2):299-307. PubMed ID: 25736040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging.
    García-Saenz JA; Ayllón P; Laig M; Acosta-Eyzaguirre D; García-Esquinas M; Montes M; Sanz J; Barquín M; Moreno F; Garcia-Barberan V; Díaz-Rubio E; Caldes T; Romero A
    BMC Cancer; 2017 Mar; 17(1):210. PubMed ID: 28330468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.
    Board RE; Wardley AM; Dixon JM; Armstrong AC; Howell S; Renshaw L; Donald E; Greystoke A; Ranson M; Hughes A; Dive C
    Breast Cancer Res Treat; 2010 Apr; 120(2):461-7. PubMed ID: 20107891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel method for PIK3CA mutation analysis: locked nucleic acid--PCR sequencing.
    Ang D; O'Gara R; Schilling A; Beadling C; Warrick A; Troxell ML; Corless CL
    J Mol Diagn; 2013 May; 15(3):312-8. PubMed ID: 23541593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative detections of TP53 gene mutations improve the diagnosis and prognostic prediction of biliary tract cancers using droplet digital PCR.
    Xiao X; Zhou J; Fang M; Ji J; Huang C; Du F; Ai W; Wang Y; Gao Z; Qiu Z; Gao C
    J Clin Lab Anal; 2022 Jan; 36(1):e24103. PubMed ID: 34813121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy.
    Zhou Y; Wang C; Zhu H; Lin Y; Pan B; Zhang X; Huang X; Xu Q; Xu Y; Sun Q
    PLoS One; 2016; 11(6):e0158143. PubMed ID: 27336598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract.
    Riener MO; Bawohl M; Clavien PA; Jochum W
    Genes Chromosomes Cancer; 2008 May; 47(5):363-7. PubMed ID: 18181165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
    Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
    Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients.
    Allouchery V; Perdrix A; Calbrix C; Berghian A; Lequesne J; Fontanilles M; Leheurteur M; Etancelin P; Sarafan-Vasseur N; Di Fiore F; Clatot F
    Sci Rep; 2021 Dec; 11(1):24041. PubMed ID: 34911971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.
    Berchuck JE; Facchinetti F; DiToro DF; Baiev I; Majeed U; Reyes S; Chen C; Zhang K; Sharman R; Uson Junior PLS; Maurer J; Shroff RT; Pritchard CC; Wu MJ; Catenacci DVT; Javle M; Friboulet L; Hollebecque A; Bardeesy N; Zhu AX; Lennerz JK; Tan B; Borad M; Parikh AR; Kiedrowski LA; Kelley RK; Mody K; Juric D; Goyal L
    Ann Oncol; 2022 Dec; 33(12):1269-1283. PubMed ID: 36089135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women.
    Chung TKH; Cheung TH; Yim SF; Yu MY; Chiu RWK; Lo KWK; Lee IPC; Wong RRY; Lau KKM; Wang VW; Worley MJ; Elias KM; Fiascone SJ; Smith DI; Berkowitz RS; Wong YF
    Gynecol Oncol; 2017 Aug; 146(2):334-339. PubMed ID: 28587748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
    Cancer Sci; 2015 Nov; 106(11):1582-9. PubMed ID: 26353837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.
    Janku F; Angenendt P; Tsimberidou AM; Fu S; Naing A; Falchook GS; Hong DS; Holley VR; Cabrilo G; Wheler JJ; Piha-Paul SA; Zinner RG; Bedikian AY; Overman MJ; Kee BK; Kim KB; Kopetz ES; Luthra R; Diehl F; Meric-Bernstam F; Kurzrock R
    Oncotarget; 2015 May; 6(14):12809-21. PubMed ID: 25980577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiplexed assays for detection of mutations in PIK3CA.
    Board RE; Thelwell NJ; Ravetto PF; Little S; Ranson M; Dive C; Hughes A; Whitcombe D
    Clin Chem; 2008 Apr; 54(4):757-60. PubMed ID: 18375489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Iwase H
    Cancer Biomark; 2018; 22(2):345-350. PubMed ID: 29689710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer.
    Ohira T; Sakai K; Matsubayashi J; Kajiwara N; Kakihana M; Hagiwara M; Hibi M; Yoshida K; Maeda J; Ohtani K; Nagao T; Nishio K; Ikeda N
    Cancer Sci; 2016 Nov; 107(11):1660-1666. PubMed ID: 27575703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.